Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia in the general population, with a growing prevalence and incidence worldwide. 1 Its prevalence increases with age, affecting more than 10% of people aged 80 years. 2, 3 In population-based studies, AF increased the risk of death up to 1.5-fold in men and 1.9-fold in women, and was a major cause of stroke and systemic embolism. [4] [5] [6] Moreover, AF impairs the normal cardiovascular physiology due to the loss of the atrioventricular synchrony, thus increasing the risk of heart failure. 7 AF and aortic stenosis share multiple common risk factors, such as age and hypertension, and aortic valve stenosis itself is associated with higher rate of AF because of pressure overload of left heart chambers. 8 AF is an independent predictor of long-term mortality and heart failure in patients with aortic stenosis 9,10 whether or not they undergo open-chest surgical aortic valve replacement (SAVR). [11] [12] [13] [14] [15] [16] [17] [18] [19] In surgical series, the reported prevalence of preexisting AF in SAVR ranges between 8% and 13%, whereas newonset AF is present in up to 40% of these patients. 11, 17, 18, [20] [21] [22] [23] [24] [25] Both pre-existing and new-onset AF are associated with increased risk of cardiac and cerebrovascular events, including mortality after SAVR. [20] [21] [22] [23] [24] [25] Transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment in patients with severe symptomatic aortic stenosis who are inoperable or at high risk for SAVR 26, 27 and growing evidence seems to confirm and extend the adverse impact of AF on outcome also in these patients. [28] [29] [30] [31] [32] This review summarizes prevalence, pathophysiology, prognosis, and treatment of AF in patients undergoing TAVI.
Definitions
Although AF is usually categorized as pre-existing AF or new-onset AF, depending on the timing of AF detection, heterogeneous definitions are present in literature for these two conditions in the TAVI setting. Pre-existing AF is defined as a history of AF (permanent, persistent, or paroxysmal) before TAVI or as the presence of AF on hospital admission or at the time of the procedure. [28] [29] [30] 33 On the contrary, when the history of AF is negative, the presence of AF occurring after TAVI is labelled as new-onset AF. [33] [34] [35] lesser the risk of the patients treated by TAVI the lower is the prevalence of pre-existing AF. 27, 38, 39 By continuous electrocardiography (ECG) monitoring, new-onset AF in the TAVI setting is also characterized by less frequent and shorter AF episodes compared with surgery. 27 Data on new-onset AF are more scattered compared with pre-existing AF, being reported in literature between 1% and 32% of cases including mixed transfemoral and transapical TAVI approach ( Table 1) . 33, 34 It is noteworthy that, consistently with surgical AVR series, new-onset AF is more frequent in TAVI patients treated transapically (6-38%) than in those treated transfemorally (<1-16%). 36, 40 This finding indicates not only a major role of procedural factors in the pathogenesis of new-onset AF, but might also explain whydifferently from pre-existing AF-the incidence of new-onset AF is less influenced by the risk profile only of the TAVI patients. To note, the 30-day rate of new-onset AF rate in studies at different (low to high) risk profile is similar.
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Pathophysiology of atrial fibrillation in patients undergoing transcatheter aortic valve implantation
As patients undergoing TAVI have aortic stenosis and several comorbidities such as hypertension, diabetes, left ventricular dysfunction, and heart failure, the development of post-TAVI AF might be in part explained by the same mechanisms that those reported in these scenarios. However, when ECG monitoring is performed before TAVI procedures in patients with not known arrhythmias, pre-existing AF is detected only in 30% of patients with new-onset AF after TAVI. 41 Therefore, more than two out of three episodes of new-onset AF seem to be directly related to the TAVI procedure itself. The pathophysiology of new-onset AF in patients undergoing TAVI remains largely unknown. However, much more is known about underlying mechanisms of post-operative AF, which might be common to post-TAVI AF. Current knowledge on pathophysiology of new-onset AF after TAVI is summarized in Figure 1 . Both, acute perioperative factors and a vulnerable substrate have been associated with an increased likelihood of re-entry and ectopic activity, which are the main mechanisms responsible for the initiation and maintenance of AF after cardiac surgery. 42 Inflammation and atrial oxidative stress might induce slow conduction, conduction barriers and short refractoriness, favouring re-entry and ectopic activity may be caused by calcium homeostasis abnormalities, which might result from autonomic nervous system activity. Both, re-entry and ectopy induce electrical and anatomical atrial remodelling characterized by changes in ion channel function, calcium homeostasis, and atrial structure such as cellular hypertrophy, activation of fibroblasts, and tissue fibrosis which, in turn, facilitate the occurrence of ectopic activity and re-entry contributing to the permanence of AF. A systemic inflammatory response is observed after TAVI. The severity of inflammation strictly depends on the TAVI access route: a lesser degree of inflammation occurs after transfemoral procedures compared with transapical procedures, 43 which are associated with a systemic inflammatory response similar to that observed after SAVR. 43, 44 Accordingly, the incidence of newonset AF is higher after transapical TAVI and approximately twothirds of new episodes of AF occur during the first 48-96 h coinciding with the peak inflammatory response. 35, 44 In addition, local inflammation and pain might have a role in the initiation of AF post-TAVI. Indeed, avoiding pericardiotomy might prevent up to 80% of episodes of new-onset AF after aortic valve replacement 45 and the use of epidural anaesthesia reduced the risk of AF after transapical TAVI. 46, 47 In animal models, autonomic nervous system activity facilitated paroxysmal AF by inducing early after-depolarization and triggered activity and sterile pericarditis was associated slow conduction. 48 In addition, volume overload and the resulting increase in atrial pressures induce acute left atrium dilatation and stretch and, consequently, shortening atrial effective refractory periods which translates into an increasing the vulnerability for AF. This mechanism is a common pathway leading to AF after cardiac surgery, heart failure, and aortic stenosis. 49, 50 In fact, aortic stenosis itself increases the risk of AF. 51 The increased left ventricle afterload caused by the obstruction to the left ventricle outflow results into left ventricle hypertrophy, diastolic dysfunction, and increased left ventricle filling pressures which, in turns, leads to an increase in left atrium pressures and, finally, left atrium remodelling with enlargement and fibrosis. 52 Both, a greater left atrium size and left atrium fibrosis are well-known predictors of AF. 53, 54 Increasing evidence supports a causal relationship between TAVI procedure and post-procedure AF regardless of the access site: the risk of post-TAVI AF is higher when using the transapical approach, which is easily understood. However, the increased risk of post-TAVI AF when using a transfemoral procedure, which largely differs from a surgical procedure (does not require pericardial opening or extracorporeal circulation, or even general anaesthesia), remains an open issue. To this regard, the rate of new-onset AF after TAVI in the Placement of Aortic Transcatheter Heart Valves (PARTNER I) cohort B, 27 PARTNER II including patients at intermediate risk, 38 and US CoreValve trial, 55 where transapical approach was not used, was indeed about 9-12%. But when considering only patients without preexisting AF, the new-onset AF rate was up to 25%. Furthermore, when systematic ECG monitoring is performed before TAVI procedures in patients with not known arrhythmias, pre-existing AF is detected in roughly one out of three patients with new-onset AF after TAVI. (67%) and specificity (61%) for predicting new-onset AF in patients treated by TAVI. 35 Procedural risk factors include balloon aortic valvuloplasty, haemodynamic instability, and the occurrence of periprocedural complications. 28, 29, 57 Nevertheless, the strongest predictor for new-onset AF seems to be the access route for TAVI. Specifically, the non-transfemoral access is associated with a significant two-to four-fold increase in the incidence of new-onset AF compared with the transfemoral access, depending on the definition of nontrasfemoral access used across studies-e.g. combination of transapical, transcarotid, trans-subclavian access vs. transapical only. 28, 29, 35, 37 This finding might be related to the fact that patients undergoing transapical TAVI are generally sicker compared with those undergoing transfemoral TAVI, 58 but an independent and direct pathogenetic role of the transapical approach as trigger for new-onset AF cannot be excluded. On the contrary, no significant interactions have been observed either between paravalvular regurgitation after TAVI and new-onset AF-despite the inherent left heart overload 59 -and related to the type of prosthesis (balloon vs. self-expanding) used. 60 Interestingly, other anatomical and procedural factors which correlate with post-TAVI arrhythmias (i.e. conduction disorders)-such as baseline electrocardiographic abnormalities, age or gender, left ventricular outflow tract diameter, implantation depth, and prosthesisto-annulus size ratio-have not been demonstrated to be predictors of AF. 61 Multiple diagnostic approaches are under investigation as potential tools to predict the onset of post-TAVI arrhythmias based on more sophisticated evaluation of anatomical (mostly computerized tomography scan based) and electrocardiographic parameters. [62] [63] [64] [65] However, little of these newer tools has been applied to AF in the TAVI context so far, and they remain an open research field. Data on predictors of pre-existing AF in TAVI patients are scant and mainly derived from a single study. 28 The clinical variables shown to be correlated to pre-existing AF were moderate to severe mitral regurgitation (MR), moderate to severe tricuspid regurgitation, and pulmonary hypertension. To note, the prominent role of procedural factors in determining the occurrence of new-onset AF together with the differences in clinical predictors and prognosis between preexisting and new-onset AF suggests that they behave as two different clinical entities, even though some overlap cannot be excluded.
Prognosis of pre-existing or newonset atrial fibrillation in the transcatheter aortic valve implantation setting
Mortality
Studies investigating the impact of AF, either pre-existing or new-onset, on mortality after TAVI have shown conflicting results ( Figure 2) . 33, 34 A meta-analysis on 14 078 patients found that only pre-existing AF but not new-onset AF was associated with increased late mortality. 33 On the contrary, a meta-analysis focused only on the new-onset AF has shown a significant increase in late mortality. 34 Finally, more recent studies [28] [29] [30] have shown a consistent increase in early and late mortality both in patients with pre-existing or newonset AF. The relationship between increased mortality and AF is multifactorial, and includes haemodynamic and functional impairment, thrombo-embolic and bleeding events, and higher rates of renal failure. [28] [29] [30] 66 In the SOURCE-XT registry, patients with AF had higher rates of rehospitalization for recurrent congestive heart failure compared with sinus rhythm. 28 Similarly, in the FRANCE-2 study the increase in 1-year mortality in the pre-existing AF group was associated with increased rehospitalization rate due to heart failure. 29 Specifically in the new-onset AF group, an interaction between heart rate (90 b.p.m.), heart failure, and mortality has been described. 29 Moreover, TAVI patients with AF have also higher incidence of conduction disturbances and bradyarrhythmias requiring permanent pacemaker implantation. 30 Also, the thrombo-embolic risk as assessed by CHA2DS2-VASC score has been related with the risk of death in these patients. 67 Despite all these observations, the AF status is not included in the available TAVI-specific risk scores. 68, 69 An additional factor, which may contribute to high rates of rehospitalization and mortality in TAVI patients with AF, is coexistent MR. The interplay among MR, AF, and mortality is complex and not fully understood in the TAVI setting. Pre-operative MR (moderate or severe) is significantly more frequent in those with either pre-existing or new-onset AF [28] [29] [30] and, on the other hand, the prevalence of AF increases together with increasing severity of MR. 70, 71 Moreover, the absence of AF is one of the observed independent predictors of MR improvement at 1 year after TAVI. 70, 71 Multiple studies including two meta-analyses have
shown that MR is associated with increased mortality after TAVI. 72, 73 Notwithstanding, in the largest specific studies on AF in TAVI patients, pre-existing AF and new-onset AF were independent predictors of 1-year mortality, whereas MR was not. 70, 71 Despite these inconsistencies in literature, increasing evidence suggests that both MR and AF may have an independent impact on mortality in TAVI patients. Conversely, MR has not proved to be the only determinant of the high post-TAVI mortality rates in those with AF.
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Stroke
Cerebrovascular events have been a shortcoming of TAVI procedures since the early phase, accounting for up to 11% of all deaths at 1-month post-procedure. 74 As far as the time-course of the cerebrovascular events is concerned, only half of these cases occur within 30 days after TAVI with one-third of them observed periprocedurally. 26, 28 Moreover, considering that about 50% of the remaining cerebrovascular events occur between 30 days and 1 year after TAVI, 27 one may argue that non-procedural factors like AF have a major impact on stroke. Notwithstanding, results are heterogeneous in literature ( Figure 3) . Previous studies failed to find an impact of pre-existing AF on early stroke, with highly heterogeneous results at long-term follow-up. 61, [75] [76] [77] These findings were confirmed by the meta-analysis by Sannino et al. 33 and other more recent studies. 28, 29 Conversely, new-onset AF showed an adverse impact on early stroke. [28] [29] [30] 61, [75] [76] [77] A recent meta-analysis by Gargiulo et al. 34 confirmed these results. The negative impact of new-onset AF compared with pre-existing AF on early stroke might be related to the heterogeneous antithrombotic regimen in these patients. 35 
Bleedings
Few reports have assessed the impact of AF on bleedings in the TAVI setting ( Figure 4) . [28] [29] [30] 57 Two large-scale studies have showed a significant association between early, but not late, major bleedings and newonset AF, without detailing on antithrombotic therapy. 28, 29 On the contrary, no interaction was observed between pre-existing AF and bleedings. Besides the role of drugs that need to be further investigated in future trials, 78-80 the increased bleeding rate in patients with AF might be related also to the high rate of renal failure in these patients. 66 
Management
The management of AF in patients undergoing TAVI should include the treatment of comorbidities and factors associated with an increased risk of AF, ventricular rate/rhythm control, and prevention of thrombo-embolic events.
Preventative strategies
The prevention of AF should start with the treatment of electrolyte and volume imbalance, pain, and anaemia which are known factors involved in the pathogenesis of AF. In addition, potential therapies targeting the mechanisms underlying the occurrence of AF after cardiac surgery have been evaluated. However, the potential benefit of these therapies in reducing the rate of AF was frequently mitigated by the occurrence of side effects. 81 Whether these preventative strategies might reduce the rate of new-onset AF after TAVI and its complications remains unknown. Furthermore, the advanced age, high risk of conduction abnormalities, and comorbidities of patients undergoing TAVI nowadays might lead to an increased risk of side effects associated with these therapies.
Rate vs. rhythm control
Regarding rate vs. rhythm control, no evidence supports one strategy over the other in TAVI patients, and consequently, no recommendations are currently available. A rhythm control strategy has failed to reduce the risk of all-cause mortality, cardiac mortality, or stroke in old patients with mild symptoms of AF in non-surgical settings. 82 Furthermore, no differences were observed in the length of hospital stay, rates of death, stroke, bleeding and, importantly, the rate of persistent AF 2 months after onset in patients with haemodynamically stable AF undergoing rhythm control with amiodarone compared with those undergoing rate control after cardiac surgery. 83 Although a strategy of rate control was associated with a higher rate of AF at 30 days, it avoided the complications associated with amiodarone. Furthermore, patients undergoing TAVI nowadays are elderly and have severe comorbidities and structural heart disease, and therefore, the clearance of antiarrhythmic drugs may be reduced and the sensitivity to proarrhythmic effects increased, in particular of bradyarrhythmias and conduction abnormalities 84 whose risk is increased after TAVI. In addition, AF has frequently no symptoms in elderly patient and thus a rhythm control strategy should not be vigorously pursued in these patients. As for cardiac surgery, beta-blockers might be reasonable as therapy of choice in the management of patients with haemodynamically stable AF after TAVI, unless contraindication is present. 3, 84 Nonetheless, rhythm control might be preferable in patients with difficult rate control or severe symptoms. In those cases, amiodarone is often used due to the presence of left ventricular hypertrophy (15 mm) or dysfunction. Importantly, a direct cardioversion should be performed in patients with new-onset AF resulting haemodynamic instability or heart failure. However, whether an electrical cardioversion might provide a clinical benefit in patients with haemodynamically stable AF after TAVI remains unknown.
Surgical ablation has been concomitantly performed with valve replacement in patients with AF before surgery. Whether catheter ablation when performed before, after or during TAVI might increase the rate of freedom from arrhythmia in patients with pre-existing AF is unknown. However, because of the risk of major complications associated with catheter ablation, in particular stroke and cardiac tamponade, and the need of high dose of anticoagulation therapy, catheter ablation should not be performed concomitantly with TAVI. In addition, the efficacy of this therapy is lower and risks higher in elderly patients and patients with structural heart disease, and therefore, it seems not reasonable to indicate catheter ablation in patients undergoing TAVI nowadays. However, whether younger patients with AF and little structural heart disease might benefit from catheter ablation remains unknown. Of note, if finally indicated, procedures should be performed in experienced centres. 84 Importantly, the need for a rhythm or rate control strategy should be evaluated during the follow-up period, and in patients with antiarrhythmic drugs initiated during the hospitalization period, it should be AF in patients undergoing TAVI evaluated the potential benefits and risk of pursuing vs. discontinuing these therapies. 85 
Antithrombotic therapy
Data regarding the antithrombotic treatment in patients undergoing TAVI are scarce, and even less information is available for patients with indication of anticoagulation therapy. Therefore, the management of antithrombotic therapy is frequently individualized according to the perceived risk of ischaemic and bleeding events, which has translated into a wide variability across centres and operators. 86 Regarding patients with chronic antithrombotic therapy, discontinuation of the therapy is generally recommended in patients on chronic anticoagulation. Pre-existent antiplatelet therapy is generally prosecuted, although in selected cases it might be discontinued before transapical or transaortic TAVI, however even this aspect has wide variability among centres.
Based on the previous experience from percutaneous coronary interventions, although with wide disparity regarding the timing of initiation, the administration of a load dose, and the duration of clopidogrel, life-long aspirin 75-100 mg daily and clopidogrel for 3-6 months are actually recommended after TAVI. 87 However, no randomized data support this recommendation and recent studies have shown that the addition of clopidogrel to aspirin might increase the risk of bleeding without a net ischaemic benefit. [88] [89] [90] In addition, almost half of patients undergoing TAVI require anticoagulation before procedures 86 and bleeding events are frequent, in particular in patients with AF, and have a major impact on mortality after TAVI. 91 As stated before, AF after TAVI appears to increase the risk of stroke and thrombo-embolic events, 34 which occur more frequently in those patients with no anticoagulation therapy initiated immediately after procedures. 35 Moreover, patients undergoing aortic valve replacement with bioprostheses are at thrombo-embolic risk, mainly during the first 3 months after the procedure and, in fact, the occurrence of AF in these patients is considered an indication for anticoagulation therapy regardless the CHADS 2 or e CHA2DS2-VASc score. 92 Whether antiplatelet therapy needs to be added to anticoagulation therapy remains unknown, although previous experiences with aortic bioprostheses suggest that anticoagulation alone might be enough to prevent thrombo-embolic events. 92 However, in TAVI patients, a combination of vitamin K antagonist and aspirin or thienopyridine is generally used, although this strategy is empirical and should be weighted against an increased risk of bleeding. 92, 93 Importantly, triple antithrombotic therapy should be avoided unless strong indication for double antiplatelet therapy, such as recent percutaneous intervention, due to the high risk of bleeding events. 94 Of note, these patients should be closely monitored for anticoagulation levels considering that a high variability of the INR is a strong independent predictor of reduced survival after valve replacement. 93 The minimal duration of AF episodes to initiate anticoagulation and the optimal timing for anticoagulation therapy remains unknown. Episodes lasting more than 30 s increased the risk of stroke after TAVI and this risk starts early after AF onset. 35 Accordingly, studies including patients with dual chamber pacemakers have shown that 5 min of AF doubled the rate of stroke. 95 Although anticoagulation therapy might be initiated early after non-complicated transfemoral procedures, it is frequently delayed at least 24 h after transapical or transaortic TAVI, considering that a too early initiation of anticoagulation has been associated with a risk of pericardial effusion after cardiac surgery, and even longer delay might be required in those patients with epidural catheters for prolonged analgesia after transapical TAVI. Uncertainty remains regarding the minimal duration of anticoagulation in patients undergoing TAVI. Although for cardiac surgery it is considered that the risk of new episodes of AF decreases after 3 months, no evidence exists on the recurrence of AF after TAVI. However, due to the high burden of AF longer ECG monitoring than those recommended for cardiac surgery might be required to rule out the recurrence of AF.
Anticoagulation therapies
Based on the results of the RE-ALIGN trial which showed an excess of thrombo-embolic and bleeding events in patients with mechanical prosthesis receiving dabigatran, new oral anticoagulants (NOACs) are not actually recommended for preventing the risk of thromboembolic events in patients with valvular AF. 96 Nonetheless, the definition of valvular AF remains unclear. Recently, it has been suggested that valvular AF should be defined as AF in patients with mechanical prosthesis or rheumatic mitral valvular disease. 97 Indeed, AF in the presence of a bioprosthetic heart valve or after valve repair appears to have a risk of thrombo-embolism similar to other forms of 'nonvalvular' AF at least after the first 3 months after the procedure, time required to complete the endothelization of the prosthesis. In fact, dabigatran was not inferior to warfarin in preventing intracardiac thrombus formation in patients with bioprosthesis. 98 Therefore, there might be a place for NOACs in AF patients undergoing TAVI, particularly after the third month, and the availability of specific antidotes makes appealing the use of NOACs in this setting, although it is not recommended in current guidelines. 79, 99 However, caution is required for the concomitant use of NOACs and antiarrhythmic drugs, severe kidney disease might contraindicate the use of these therapies, and adjustments might be required in very old patients. In addition, as for antivitamin K agents, whether an antiplatelet agents need to be added to NOACs in TAVI patients remains unknown. Finally, in patients with contraindication for anticoagulation and non-valvular AF, the use of percutaneous left atrium appendage closure prevented the occurrence of thrombo-embolic events and reduced the risk of bleeding. 100, 101 However, data are scarce in the TAVI setting and no strong recommendations can be made so far.
Clinical and research outlook:
what can we do to achieve further improvement?
Besides the existing global strategies to improve the outcomes of patients with AF the following specific issues may concern patients undergoing TAVI:
(1) Silent AF is frequent before TAVI. 41 Performing ECG monitoring before TAVI can help to identify previously unknown AF which may translate into the implementation of specific therapies to prevent complications. A positive effect of such strategies is likely but remains to be proved. (2) Future studies will determine the potential usefulness of preventive strategies to reduce the occurrence of new-onset AF.
• Current experience shows a continuous increase in the use of transfemoral approach, which is likely to have a favourable effect on AF since using non-transfemoral approaches, especially transapical, carries a three-fold greater risk of new-onset AF. Fortunately, the use of transfemoral approach will continue to increase following the development of new generation TAVI devices with smaller shafts. 102 In addition, the new prostheses will further reduce vascular and haemorrhagic complications which might increase the risk of developing AF. 29 • Amiodarone and anti-inflammatory treatments were used to decrease post-operative AF after cardiac surgery but they did not show a significant effect on hard endpoints such as death or stroke. These agents could be tested in the field of TAVI, especially when using a non-transfemoral approach. New-onset AF increases not only the risk of thrombo-embolism but also the haemorrhagic events in patients treated by TAVI. This poses the problem of the optimization of antithrombotic treatment particularly in the high-risk population of patients with AF who require the combination of vitamin K blockers and antiplatelet agents. Current antithrombotic management after TAVI is not supported by evidence. 87 In the large registries on TAVI, antithrombotic therapy is either not recorded or not standardized thus there is a need for better evidence. Several randomized clinical trials are currently ongoing in order to answer the question of the best antithrombotic regime:
• POPular TAVI (Antiplatelet Therapy for Patients Undergoing
Transcatheter Aortic Valve Implantation; ClinicalTrials.gov Identifier: NCT02247128) where oral anticoagulants are compared with the combination of oral anticoagulants and clopidogrel.
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• GALILEO (Global multicentre, open-label, randomized, eventdriven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement to Optimize clinical outcomes will compare rivaroxaban-based; ClinicalTrials.gov Identifier: NCT02556203) comparing aspirin plus rivaroxaban vs. aspirin plus clopidogrel.
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• ATLANTIS (Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic Ischaemic and Haemorrhagic Events after TransAortic Valve Implantation for Aortic Stenosis; ClinicalTrials.gov Identifier: NCT02664649) where Apixaban is compared with Vitamin K blockers. 80 These trials will also help to know for how long it is necessary to continue anticoagulation in the context of AF that develops post-TAVI.
(4) Alternative treatment strategies that can be performed in combination with TAVI may also play a role. Preliminary reports suggest that left atrial appendage occlusion is feasible and could be of potential interest, in particular in patients with contraindications for oral anticoagulation. 103 One randomized clinical trial 104 and a few observational studies 105 suggest that the use of cerebral embolic protection devices during TAVI may lead to smaller new brain lesions and better preservation of neurocognitive performance. This needs to be confirmed by larger randomized trials. However, one limitation of this strategy is that such devices can only prevent the events which occur during TAVI which represents a small proportion of strokes. (5) Data supporting improved outcomes from restoration or maintenance of sinus rhythm in the general population are lacking and whether such strategies might benefit TAVI patients is not known.
Conclusion
AF (pre-existing and new-onset AF) is a frequent finding in patients with severe aortic stenosis undergoing TAVI. The two types of AF have different predictors and prognosis and seem to be two different pathophysiologic entities, even though some overlap cannot be excluded. AF is associated with increased mortality and adverse ischaemic and haemorrhagic events after TAVI and as such needs to be prevented, diagnosed, and treated properly. However, further studies are needed to better clarify whether AF is a merely a marker of increased risk or an independent risk factor in patients treated by TAVI.
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